Winton Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Winton Group’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-119,676	Closed	-$340K	–	575
2024 Q1	$340K	Buy	+119,676	New	+$1.57M	0.02%	514

Other funds holding AMLX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Winton Group's AMLX Position: Q2 2024 in Review

Winton Group sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2024, closing a stake of 119,676 shares — an estimated $340K sold.

Winton Group first reported a position in AMLX in Q1 2024 and held it in 1 quarter. The position peaked at $340K in Q1 2024. 119 funds tracked by Wall St. Rank hold AMLX as of Q2 2024.

Winton Group reported no remaining Amylyx Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Winton Group sold 119,676 Amylyx Pharmaceuticals shares in Q2 2024, an estimated $340K.
Winton Group first reported a position in Amylyx Pharmaceuticals in Q1 2024 and held it in 1 quarter.
Winton Group's Amylyx Pharmaceuticals position peaked at $340K in Q1 2024.
119 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2024.

Based on Winton Group's 13F filing for Q2 2024, filed 9 Aug 2024.